46,700 Shares in Xencor, Inc. (NASDAQ:XNCR) Purchased by Polar Asset Management Partners Inc.

Polar Asset Management Partners Inc. acquired a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 46,700 shares of the biopharmaceutical company's stock, valued at approximately $939,000. Polar Asset Management Partners Inc. owned about 0.07% of Xencor at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of XNCR. Quarry LP purchased a new stake in Xencor in the 2nd quarter worth approximately $36,000. KBC Group NV lifted its holdings in Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company's stock worth $63,000 after purchasing an additional 1,213 shares in the last quarter. SG Americas Securities LLC bought a new position in Xencor in the 2nd quarter worth approximately $154,000. XTX Topco Ltd purchased a new stake in Xencor during the 2nd quarter valued at approximately $196,000. Finally, Rockefeller Capital Management L.P. bought a new stake in shares of Xencor during the third quarter valued at approximately $205,000.

Insider Activity

In related news, CEO Bassil I. Dahiyat sold 49,278 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $24.07, for a total value of $1,186,121.46. Following the completion of the sale, the chief executive officer now owns 352,615 shares in the company, valued at approximately $8,487,443.05. The trade was a 12.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Alan Bruce Montgomery sold 13,301 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $27.03, for a total value of $359,526.03. Following the completion of the transaction, the director now directly owns 9,140 shares in the company, valued at approximately $247,054.20. This trade represents a 59.27 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 136,050 shares of company stock valued at $3,277,609. 5.23% of the stock is currently owned by insiders.

Analyst Ratings Changes

XNCR has been the topic of a number of research reports. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and lifted their price target for the company from $20.00 to $30.00 in a report on Monday. JPMorgan Chase & Co. boosted their target price on Xencor from $27.00 to $28.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. BMO Capital Markets reaffirmed an "outperform" rating and issued a $34.00 price objective (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Royal Bank of Canada increased their target price on Xencor from $31.00 to $34.00 and gave the company an "outperform" rating in a research report on Thursday, September 26th. Finally, Wedbush restated an "outperform" rating and issued a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $36.50.

Xencor Trading Up 0.1 %

NASDAQ XNCR traded up $0.02 on Friday, hitting $25.34. 413,590 shares of the stock were exchanged, compared to its average volume of 609,528. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $27.24. The firm has a market capitalization of $1.77 billion, a P/E ratio of -7.92 and a beta of 0.69. The stock has a fifty day moving average price of $22.51 and a two-hundred day moving average price of $20.64.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.98) by $0.27. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $10.70 million during the quarter, compared to analysts' expectations of $14.59 million. During the same period in the previous year, the company earned ($0.40) EPS. The firm's revenue for the quarter was down 81.9% compared to the same quarter last year. Research analysts forecast that Xencor, Inc. will post -3.71 EPS for the current fiscal year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.